company? Let’s change
that.
Don't see your company?
Create a company profileDefining and optimising TBI diagnosis and prognosis to maximise patient outcomes.To increase the understanding of brain related injury with particular emphasis on concussion (mTBI) through ongoing research and education, and to ultimately validate a biomarker(s) that will be used in combination with dedicated point of care (POC) device as a definitive diagnostic/prognostic tool. A group of dedicated professionals working in collaboration with medical and scientific experts worldwide, using robust clinical trials across cohorts to assist in the validation of biomarkers in combination with other modalities to definitively diagnose TBI with emphasis on mild TBI (mTBI)/concussion. With extensive experience in fields covering biomedicine, research, diagnostics and development, GLIA is well placed to make much needed, valuable discoveries in this area. We envisage GLIA as being a 'central hub' between multiple synergistic parties both here in Australasia and worldwide, to maximise individual and group findings. It is our firm belief that diagnostics used for TBI will be a combination not only of individual biomarkers, but also multiple modalities.
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
Psylo is a drug development company focused on next generation psychedelics; our goal is to make broadly accessible medicines as improved treatments to currently available SSRI medications, using psychedelic molecules as the starting point. We are building a pipeline of novel molecules with the ultimate goal of taking leading candidates through to clinical trials.
Ancestry is the global leader in family history and consumer genomics. Every day, around the world, we help curious people like you embark on journeys of personal discovery to enrich lives. With our unparalleled collection of more than 40 billion records from more than 80 countries and 23+ million people in our growing DNA network, Ancestry helps customers discover their family story and gain a new level of understanding about their lives. For 40 years, we’ve built trusted relationships with millions of people who have chosen us as the platform for discovering, preserving and sharing their story.
Dexcom Corporation is a pioneer and global leader in continuous glucose monitoring (CGM). Dexcom began as a small company with a big dream: To forever change how diabetes is managed. To unlock information and insights that drive better health outcomes. Here we are 25 years later, having pioneered an industry. And we're just getting started. We are broadening our vision beyond diabetes to empower people to take control of health. That means personalized, actionable insights aimed at solving important health challenges. To continue what we've started: Improving human health. We are driven by over 10,000 ambitious, passionate people worldwide who are willing to fight like warriors to earn the trust of our customers by listening, serving with integrity, thinking big, and being dependable. We've already changed millions of lives and we're ready to change millions more. Our future ambition is to become a leading consumer health technology company while continuing to develop solutions for serious health conditions. We'll get there by constantly reinventing unique biosensing-technology experiences. Though we've come a long way from our small company days, our dreams are bigger than ever. The opportunity to improve health on a global scale stands before us
At the heart of our mission lies the fusion of nature and science, driven by the desire to offer the world nature-identical proteins that are as familiar as they are sustainable. What sets us apart? No animals are involved, no additional land is required, and we are firmly committed to conserving water. How We Achieve It: Through the remarkable field of biotech, we unlock the boundless potential of proteins with the power of precision fermentation. Imagine the possibilities: our impact extends far beyond the food and beverage industry, encompassing nutraceuticals, infant nutrition, and a vast spectrum in between.
We exist to help make medical research breakthroughs happen by expediting and enabling a better clinical trial process - for everybody. Our suite of purpose-built and owned Evrima products and services are born of the clinical trial sector and are inherently solutions-focused. We efficiently and accurately connect a diverse range of trial participants, researchers and clinicians, delivering an optimum clinical trial recruitment and management experience.
AdvanCell is a clinical stage radiopharmaceutical company developing an innovative pipeline of 212Pb-based Targeted Alpha Therapies for cancer patients. AdvanCell’s platform technology addresses the most significant challenge in Targeted Alpha Therapy – the reliable and scalable supply of isotope. AdvanCell’s novel drug discovery, preclinical processes, and state-of-the-art facilities leverage daily access to 212Pb, the ideal isotope for Targeted Alpha Therapy. For more information, please visit www.advancell.com.au
EngeneIC is a biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for the targeted delivery of chemotherapeutics and functional nucleic acids in cancer. The EDV™ is a first-in-class Cyto-Immunotherapy platform.
At Eucalyptus, we run a trusted group of digital healthcare clinics on our telehealth platform including Pilot (men’s health), Kin (fertility), Software (dermatology) and Juniper (weight loss and menopause). Our mission is to bring high-touch, high-quality healthcare to patients around the world by empowering practitioners with technology. Since 2019, we’ve facilitated over one million consultations across Australia, the UK and Germany. With every consult, we’re breaking down boundaries to better health by providing better access to care, stigma-free experiences, and continuous support. Our commitment to providing better patient experiences is matched by our stellar record of patient safety. To learn more about Eucalyptus, visit our website
Building with biology. Hydrogen and Renewable Energy, On-site and On-Demand
CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, CSL Plasma and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra
Work Your Passion. Live Your Purpose.